Piper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Cogent Biosciences (COGT – Research Report) today and set a price target ...
Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price ...
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
Le Lézard14h
Adimab Provides Update on Pipeline
Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that five therapeutic products containing molecules discovered ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
sicklecellanemianews17h
Orna, Vertex partner on gene-editing therapies for SCD, TDT
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...
Cure Today9h
FDA Grants Priority Review to Sunvozertinib for EGFR Exon20+ NSCLC
The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.
precisionmedicineonline16h
Intellia Readying for Commercial Activities, First Product Launch in 2027
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...